メンタルヘルス臨床試験の世界市場

メンタルヘルス臨床試験の世界市場は2030年までに46億米ドルに到達

2024年に31億米ドルと推定されるメンタルヘルス臨床試験の世界市場は、2024年から2030年にかけてCAGR 6.8%で成長し、2030年には46億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるフェーズiは、CAGR 5.3％を記録し、分析期間終了までに19億米ドルに達すると予測されます。フェーズIIセグメントの成長率は、分析期間でCAGR 8.2％と推定されます。

米国市場は8億4,630万米ドルと推定、中国はCAGR10.4％で成長予測

米国のメンタルヘルス臨床試験市場は、2024年に8億4,630万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR10.4%で推移し、2030年には予測市場規模9億4,360万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ3.5%と6.5%と予測されています。欧州では、ドイツがCAGR 4.4%で成長すると予測されています。

世界のメンタルヘルス臨床試験市場- 主要動向と促進要因のまとめ

メンタルヘルス臨床試験とは何か、なぜ重要なのか？

メンタルヘルス臨床試験とは、うつ病、不安障害、統合失調症、双極性障害などの精神疾患に対する新しい治療法や介入の安全性、有効性、全体的な影響を評価するために実施される調査研究です。これらの臨床試験は、提案された治療法が効果的に症状を緩和し、QOLを改善し、既存の治療法に反応しなかった患者に新たな解決策を提供できる可能性があるかどうかを判断するのに役立つため、医薬品開発プロセスの重要な要素となっています。臨床試験は通常、安全性に焦点を当てた小規模な第I相試験から、治療の有効性を確認することを目的とした大規模な第III相試験まで、いくつかのフェーズで実施されます。

メンタルヘルス臨床試験には、医薬品、行動療法、医療機器、デジタルヘルスソリューションなど、さまざまな種類の介入が含まれることが多いです。調査は、参加者の権利と幸福の保護を重視し、厳格な倫理的ガイドラインの下で実施されます。メンタルヘルスの問題が世界的に増加し続ける中、こうした臨床試験の重要性はかつてないほど明白になっています。これらの試験は、治療ガイドラインに必要なデータを提供し、ヘルスケア専門家がより正確な診断を下し、最終的にメンタルヘルス障害に苦しむ人々の転帰を改善するのに役立ちます。

メンタルヘルス臨床試験の最新動向は？

メンタルヘルス臨床試験の最も重要な動向の1つは、デジタルヘルス技術の利用の増加です。遠隔医療、ウェアラブルデバイス、モバイルヘルスアプリの台頭により、多くのメンタルヘルスの臨床試験は、患者の行動、治療アドヒアランス、全体的な精神的幸福に関するリアルタイムのデータを収集するデジタルツールを取り入れています。これらのテクノロジーは、より頻繁で詳細なモニタリングを可能にし、従来の臨床環境では不可能であった症状、副作用、回復の進捗状況を調査者が追跡することを可能にします。さらに、デジタルヘルスツールは遠隔地での試験実施に柔軟性をもたらし、特に十分なサービスを受けていない地域や地方の人々にとっては、参加への障壁が軽減されます。

さらに、個別化医療への関心の高まりは、メンタルヘルス臨床試験に変化をもたらしています。研究者は、個人の遺伝的体質、ライフスタイル、特定のメンタルヘルス状態に合わせた治療にますます力を注いでいます。このアプローチは、しばしば精密精神医学と呼ばれ、患者のユニークな特性に基づいて、より良い結果をもたらす、より効果的な治療法を開発することを目的としています。例えば、どの患者が特定の薬物療法や治療法に反応しやすいかを予測するバイオマーカーを特定するために、遺伝子検査が臨床試験に組み込まれています。このような個別化医療へのシフトは、臨床試験の成功率を高め、最終的には精神疾患のより的を絞った効果的な治療につながることが期待されています。

なぜメンタルヘルス臨床試験の需要が高まっているのでしょうか？

メンタルヘルス臨床試験の需要は、メンタルヘルス疾患の世界の負担の増加により、着実に増加しています。世界保健機関（WHO）によると、うつ病は今や世界の障害原因の第一位であり、不安障害も最も一般的な精神疾患の一つです。COVID-19のパンデミックは、孤立、ストレス、不確実性によるメンタルヘルス状態の著しい急増によって、これらの問題を悪化させています。このため、新たな治療法に対する緊急のニーズが生まれ、メンタルヘルス研究への投資が活発化しています。その結果、製薬会社、研究機関、ヘルスケア・プロバイダーは、増大する需要に対応するため、医薬品、非医薬品にかかわらず、新規治療法の研究への取り組みを強化しています。

さらに、メンタルヘルスが全体的な幸福の重要な要素であるとの認識が高まり、臨床試験の必要性がさらに高まっています。政府、組織、擁護団体はメンタルヘルスをより重視し、政策立案者にメンタルヘルス研究のための資金を優先的に提供するよう求めています。このようなメンタルヘルスに対する社会的な注目の高まりは、セクターを超えた協力関係の強化につながり、イノベーションを促進し、より多くの治療選択肢の開発を促しています。さらに、より良い治療を求める患者のアドボカシーが高まっています。多くの精神疾患患者が、現在の治療法では十分な緩和が得られないと感じているからです。これらの要因により、メンタルヘルス患者の多様なニーズに対応することを目的とした、より強固で多様な臨床試験に対する強い需要が生まれています。

メンタルヘルス臨床試験市場の主な成長促進要因は？

メンタルヘルス臨床試験市場の成長は、主に世界の精神疾患の有病率の増加など、いくつかの要因によってもたらされます。うつ病、不安神経症、双極性障害、統合失調症などの疾患の世界の負担が増加し続けているため、新たな治療や介入が急務となっています。このため、メンタルヘルス研究に対する官民両部門からの投資が増加し、より多様な臨床試験が支援されています。より効果的な治療法に対する需要の高まりは、メンタルヘルスにおけるアンメット・メディカル・ニーズの高さと相まって、引き続き市場の成長を後押ししています。

もう一つの重要な推進力は、デジタル臨床試験と分散型臨床試験の拡大です。遠隔医療、遠隔モニタリングツール、モバイルアプリケーションなどのデジタルヘルス技術の統合により、より柔軟でスケーラブルな臨床試験が可能になります。これらの技術は、患者の募集を促進し、データ収集を改善し、より広い地域で臨床試験を実施することを可能にします。これらのツールの使用は、臨床試験の効率を高めるだけでなく、物流上の障壁や地理的制限のために従来の臨床試験に参加できなかった患者へのアクセスを開放します。

さらに、規制の進歩もメンタルヘルス臨床試験市場の成長を加速させる上で極めて重要な役割を果たしています。FDAやEMAなどの規制機関は、精神疾患への対応が急務であることを認識し、デジタル療法やその他の非伝統的な介入を含む新規治療法の承認プロセスを合理化しています。こうした規制の改善は、より多くの企業のメンタルヘルス領域への参入を促し、革新的なソリューションをより早く市場に投入することにつながっています。さらに、遺伝子研究やバイオマーカー研究による個別化医療のトレンドの高まりは、治療の精度を向上させ、臨床試験の失敗率を低下させる、より的を絞った臨床試験の創出を後押ししています。市場情勢が進化を続ける中、これらの要因が市場のさらなる成長とイノベーションを促進すると予想されます。

セグメント

フェーズ（第I相、第II相、第III相、第IV相）;疾患（不安障害、うつ病、双極性感情障害、解離・解離性障害、統合失調症、その他）;試験デザイン（介入、観察、その他）;スポンサー（製薬・バイオテクノロジー企業、政府機関、その他）

調査対象企業の例

• Ambrosia Treatment Center
• Caidya
• CenExel Clinical Research
• Compass Pathways
• Eli Lilly and Company
• Hightop Health
• ICON plc
• IQVIA
• Labcorp Drug Development
• Mayo Clinic
• Medpace
• MindMed
• National Institute of Mental Health（NIMH）
• Numinus Wellness Inc.
• Parexel International Corporation
• PPD（Thermo Fisher Scientific）
• Sofpromed
• Syneos Health
• Usona Institute
• Worldwide Clinical Trials

AIインテグレーション

私たちは、検証された専門家のコンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、LLMや業界固有のSLMを照会する一般的な規範に従う代わりに、ビデオ記録、ブログ、検索エンジン調査、膨大な量の企業、製品/サービス、市場データなど、世界中の専門家からキュレートされたコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Mental Health Clinical Trials Market to Reach US$4.6 Billion by 2030

The global market for Mental Health Clinical Trials estimated at US$3.1 Billion in the year 2024, is expected to reach US$4.6 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2024-2030. Phase I, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$1.9 Billion by the end of the analysis period. Growth in the Phase II segment is estimated at 8.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$846.3 Million While China is Forecast to Grow at 10.4% CAGR

The Mental Health Clinical Trials market in the U.S. is estimated at US$846.3 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$943.6 Million by the year 2030 trailing a CAGR of 10.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.5% and 6.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.4% CAGR.

Global Mental Health Clinical Trials Market - Key Trends & Drivers Summarized

What Are Mental Health Clinical Trials and Why Are They Important?

Mental health clinical trials are research studies conducted to evaluate the safety, efficacy, and overall impact of new treatments or interventions for mental health conditions, such as depression, anxiety, schizophrenia, and bipolar disorder. These trials are a critical component of the drug development process, as they help determine whether a proposed treatment can effectively alleviate symptoms, improve quality of life, and potentially offer new solutions for individuals who have not responded to existing therapies. Clinical trials are typically conducted in several phases, ranging from small-scale Phase I trials focusing on safety, to large-scale Phase III trials aimed at confirming the efficacy of the treatment.

Mental health clinical trials often involve different types of interventions, such as pharmaceuticals, behavioral therapies, medical devices, or digital health solutions. The research is conducted under stringent ethical guidelines, with an emphasis on protecting the rights and well-being of participants. As mental health issues continue to rise globally, the importance of these trials has never been more apparent. They provide the data necessary to inform treatment guidelines, help healthcare professionals make more accurate diagnoses, and ultimately improve outcomes for individuals suffering from mental health disorders.

What Are the Latest Trends in Mental Health Clinical Trials?

One of the most significant trends in mental health clinical trials is the increasing use of digital health technologies. With the rise of telemedicine, wearable devices, and mobile health apps, many mental health trials are incorporating digital tools to collect real-time data on patient behavior, treatment adherence, and overall mental well-being. These technologies allow for more frequent and detailed monitoring, enabling researchers to track symptoms, side effects, and recovery progress in ways that were not possible in traditional clinical settings. Furthermore, digital health tools provide the flexibility to conduct remote trials, reducing barriers to participation, particularly for individuals in underserved or rural areas.

Additionally, the growing interest in personalized medicine is transforming mental health clinical trials. Researchers are increasingly focusing on tailoring treatments to an individual’s genetic makeup, lifestyle, and specific mental health conditions. This approach, often referred to as precision psychiatry, aims to develop more effective therapies that can provide better outcomes for patients based on their unique characteristics. For instance, genetic testing is being integrated into clinical trials to identify biomarkers that predict which patients are more likely to respond to specific medications or therapies. This shift towards personalized care promises to increase the success rates of clinical trials and ultimately lead to more targeted, effective treatments for mental health disorders.

Why Is the Demand for Mental Health Clinical Trials Increasing?

The demand for mental health clinical trials has been steadily increasing due to the rising global burden of mental health disorders. According to the World Health Organization, depression is now the leading cause of disability worldwide, and anxiety disorders are also among the most common mental health conditions. The COVID-19 pandemic has exacerbated these issues, with significant spikes in mental health conditions due to isolation, stress, and uncertainty. This has created an urgent need for new treatment options and has catalyzed investment in mental health research. As a result, pharmaceutical companies, research institutions, and healthcare providers are ramping up efforts to explore novel therapies, both pharmaceutical and non-pharmaceutical, to address the growing demand.

Additionally, there is an increased recognition of mental health as a critical component of overall well-being, which has further amplified the need for clinical trials. Governments, organizations, and advocacy groups are putting more emphasis on mental health, urging policymakers to prioritize funding for mental health research. This broader societal focus on mental health has led to greater collaboration across sectors, fostering innovation and encouraging the development of more treatment options. Furthermore, there is growing patient advocacy for better treatments, as many individuals with mental health conditions feel that current therapies do not provide sufficient relief. These factors have created a strong demand for more robust and varied clinical trials aimed at addressing the diverse needs of mental health patients.

What Are the Key Growth Drivers in the Mental Health Clinical Trials Market?

The growth in the mental health clinical trials market is driven by several factors, primarily the increasing prevalence of mental health disorders worldwide. As the global burden of conditions such as depression, anxiety, bipolar disorder, and schizophrenia continues to rise, there is an urgent need for new treatments and interventions. This has led to higher levels of investment from both public and private sectors in mental health research, supporting a more diverse range of clinical trials. The rising demand for more effective therapies, coupled with the high unmet medical need in mental health, continues to propel growth in the market.

Another significant driver is the expansion of digital and decentralized clinical trials. The integration of digital health technologies, such as telemedicine, remote monitoring tools, and mobile applications, allows for more flexible and scalable clinical trials. These technologies facilitate greater patient recruitment, improve data collection, and enable trials to be conducted across broader geographic regions. The use of these tools not only enhances the efficiency of trials but also opens up access to patients who may not have been able to participate in traditional trials due to logistical barriers or geographic limitations.

Additionally, regulatory advancements have played a pivotal role in accelerating the growth of the mental health clinical trials market. Regulatory bodies, such as the FDA and EMA, have recognized the urgency of addressing mental health disorders and have streamlined approval processes for novel treatments, including digital therapies and other non-traditional interventions. These regulatory improvements have encouraged more companies to enter the mental health space, bringing innovative solutions to market faster. Furthermore, the growing trend of personalized medicine, driven by genetic and biomarker research, is helping to create more targeted trials that improve the precision of treatments and reduce trial failure rates. As the mental health clinical trials landscape continues to evolve, these factors are expected to fuel further growth and innovation in the market.

SCOPE OF STUDY:

The report analyzes the Mental Health Clinical Trials market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Phase (Phase I, Phase II, Phase III, Phase IV); Disorder (Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders, Schizophrenia, Others); Study Design (Interventional, Observational, Others); Sponsor (Pharma & Biotech Companies, Government Agencies, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Ambrosia Treatment Center
• Caidya
• CenExel Clinical Research
• Compass Pathways
• Eli Lilly and Company
• Hightop Health
• ICON plc
• IQVIA
• Labcorp Drug Development
• Mayo Clinic
• Medpace
• MindMed
• National Institute of Mental Health (NIMH)
• Numinus Wellness Inc.
• Parexel International Corporation
• PPD (Thermo Fisher Scientific)
• Sofpromed
• Syneos Health
• Usona Institute
• Worldwide Clinical Trials

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Mental Health Clinical Trials - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Mental Health Burden Throws the Spotlight on Accelerated Clinical Trial Activity
  • Increased Government Funding and Grants Propels Growth in Mental Health Research Programs
  • Integration of Digital Therapeutics and Telehealth Solutions Drives Adoption of Hybrid Trial Models
  • Growing Emphasis on Personalized Medicine Expands Addressable Market for Targeted Mental Health Trials
  • Advances in Biomarker Research Strengthen the Business Case for Precision Psychiatry Trials
  • Artificial Intelligence and Machine Learning Tools Accelerate Demand for Smarter, Faster Trial Designs
  • Expansion of Decentralized Clinical Trials (DCTs) Spurs Inclusion of Hard-to-Reach Populations
  • Rising Prevalence of Depression and Anxiety Disorders Generates Demand for Novel Therapeutics and Trials
  • Regulatory Push for Diversity and Inclusion in Clinical Trials Drives Broader Patient Recruitment
  • Increased Pharma-Biotech Collaborations in CNS Drug Development Sustains Long-Term Growth in the Sector
  • Integration of Wearable Devices and Remote Monitoring Technologies Drives Adoption of Real-Time Data Capture
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Mental Health Clinical Trials Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Mental Health Clinical Trials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Mental Health Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Phase I by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Phase I by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Phase II by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Phase II by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Phase III by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Phase III by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Phase IV by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Phase IV by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Anxiety Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Anxiety Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Anxiety Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Depression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Depression by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Depression by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Bipolar affective disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Bipolar affective disorder by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Bipolar affective disorder by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Dissociation & dissociative disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Dissociation & dissociative disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Dissociation & dissociative disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Schizophrenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Schizophrenia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Schizophrenia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Interventional by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Interventional by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Interventional by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Observational by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Observational by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Observational by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Other Study Designs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Other Study Designs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Other Study Designs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Pharma & Biotech Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Pharma & Biotech Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Government Agencies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Government Agencies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Government Agencies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 50: World Recent Past, Current & Future Analysis for Other Sponsors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 51: World Historic Review for Other Sponsors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: World 15-Year Perspective for Other Sponsors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Mental Health Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 53: USA Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 62: USA Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: USA Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: USA 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 74: Canada Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Canada Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Canada 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• JAPAN
  • Mental Health Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 86: Japan Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: Japan Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: Japan 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• CHINA
  • Mental Health Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 89: China Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: China 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: China 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 98: China Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: China Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: China 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• EUROPE
  • Mental Health Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Mental Health Clinical Trials by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Mental Health Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: Europe Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: Europe 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• FRANCE
  • Mental Health Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 116: France Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: France 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: France 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: France 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 125: France Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: France Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: France 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• GERMANY
  • Mental Health Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Germany 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Germany 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Germany 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 137: Germany Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Germany Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Germany 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Italy 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Italy 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Italy 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 149: Italy Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Italy Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: Italy 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Mental Health Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 152: UK Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: UK 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: UK 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: UK 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 161: UK Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: UK Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: UK 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Spain 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Spain 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Spain 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 173: Spain Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Spain Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Spain 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Russia 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Russia 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Russia 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 185: Russia Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Russia Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Russia 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 197: Rest of Europe Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Rest of Europe Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Rest of Europe 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Mental Health Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Mental Health Clinical Trials by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Mental Health Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Asia-Pacific 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Mental Health Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Australia 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Australia 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Australia 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 224: Australia Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Australia Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: Australia 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• INDIA
  • Mental Health Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 227: India Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: India 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: India 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: India 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 236: India Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: India Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: India 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: South Korea 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: South Korea 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: South Korea 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 248: South Korea Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: South Korea Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: South Korea 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 260: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Rest of Asia-Pacific Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Rest of Asia-Pacific 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Mental Health Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Mental Health Clinical Trials by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Mental Health Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Latin America 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Latin America Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Latin America 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Argentina 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Argentina 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Argentina 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 287: Argentina Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Argentina Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Argentina 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Brazil 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Brazil 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Brazil 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 299: Brazil Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Brazil Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Brazil 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Mexico 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Mexico 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Mexico 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 311: Mexico Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Mexico Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Mexico 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 323: Rest of Latin America Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 324: Rest of Latin America Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Rest of Latin America 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Mental Health Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Mental Health Clinical Trials by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Mental Health Clinical Trials by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Middle East 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Middle East Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Middle East 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Iran 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Iran 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Iran 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 350: Iran Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Iran Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Iran 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Israel 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Israel 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Israel 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 362: Israel Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Israel Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Israel 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 374: Saudi Arabia Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: Saudi Arabia Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: Saudi Arabia 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: UAE 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: UAE 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: UAE 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 386: UAE Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: UAE Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: UAE 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 398: Rest of Middle East Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Rest of Middle East Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Rest of Middle East 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030
• AFRICA
  • Mental Health Clinical Trials Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Mental Health Clinical Trials by Phase - Phase I, Phase II, Phase III and Phase IV Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Africa 15-Year Perspective for Mental Health Clinical Trials by Phase - Percentage Breakdown of Value Sales for Phase I, Phase II, Phase III and Phase IV for the Years 2015, 2025 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Mental Health Clinical Trials by Disorder - Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 406: Africa 15-Year Perspective for Mental Health Clinical Trials by Disorder - Percentage Breakdown of Value Sales for Other Disorders, Anxiety Disorders, Depression, Bipolar affective disorder, Dissociation & dissociative disorders and Schizophrenia for the Years 2015, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Mental Health Clinical Trials by Study Design - Interventional, Observational and Other Study Designs Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 409: Africa 15-Year Perspective for Mental Health Clinical Trials by Study Design - Percentage Breakdown of Value Sales for Interventional, Observational and Other Study Designs for the Years 2015, 2025 & 2030
  • TABLE 410: Africa Recent Past, Current & Future Analysis for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 411: Africa Historic Review for Mental Health Clinical Trials by Sponsor - Pharma & Biotech Companies, Government Agencies and Other Sponsors Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 412: Africa 15-Year Perspective for Mental Health Clinical Trials by Sponsor - Percentage Breakdown of Value Sales for Pharma & Biotech Companies, Government Agencies and Other Sponsors for the Years 2015, 2025 & 2030

IV. COMPETITION